MA34460B1 - Préparation d'un revêtement de particules - Google Patents

Préparation d'un revêtement de particules

Info

Publication number
MA34460B1
MA34460B1 MA35652A MA35652A MA34460B1 MA 34460 B1 MA34460 B1 MA 34460B1 MA 35652 A MA35652 A MA 35652A MA 35652 A MA35652 A MA 35652A MA 34460 B1 MA34460 B1 MA 34460B1
Authority
MA
Morocco
Prior art keywords
isobutyloxyphenyl
cyano
methyl
carboxylic acid
thiazole carboxylic
Prior art date
Application number
MA35652A
Other languages
English (en)
Inventor
Kazuhiro Nakamura
Teppei Ogawa
Tomoya Tagawa
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45441336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34460(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MA34460B1 publication Critical patent/MA34460B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE PRÉPARATION QUI, DANS UN COMPRIMÉ SE DÉSINTÉGRANT RAPIDEMENT APRÈS ADMINISTRATION ORALE ET AYANT POUR PRINCIPE ACTIF L'ACIDE 2-(3-CYANO-4-ISOBUTYLOXYPHÉNYL)-4-MÉTHYL-5-THIAZOLE CARBOXYLIQUE, N'ENTRAÎNE FONDAMENTALEMENT PAS D'IRRITATION DE LA BOUCHE OU DE LA GORGE, CONSERVE UNE BONNE APTITUDE À LA DISSOLUTION ET UNE BONNE DÉSINTÉGRATION ORALE MÊME LORSQU'ELLE EST CONSERVÉE DANS DES CONDITIONS DE TEMPÉRATURE ÉLEVÉE OU D'HUMIDITÉ ÉLEVÉE. LE COMPRIMÉ DE L'INVENTION SE DÉSINTÉGRANT RAPIDEMENT APRÈS UNE ADMINISTRATION ORALE EST FORMÉ POUR CONTENIR DES PARTICULES COMPRENANT DES PARTICULES NUCLÉAIRES QUI CONTIENNENT DE L'ACIDE 2-(3-CYANO-4-ISOBUTYLOXYPHÉNYL)-4-MÉTHYL-5-THIAZOLE CARBOXYLIQUE, QUI SONT COUVERTES PAR UNE COUCHE CONTENANT UN COPOLYMÈRE D'ACIDE MÉTHACRYLIQUE, ET QUI SONT EN OUTRE ENROBÉES D'UNE COUCHE EXTÉRIEURE CONTENANT DES SUCRES SOLUBLES DANS L'EAU, DE TELLE MANIÈRE QU'APRÈS DEUX SEMAINES DE STOCKAGE DANS DES CONDITIONS IMPLIQUANT LE CAPUCHON OUVERT À 40°C/75 % D'HR, UN TEST DE DISSOLUTION RÉALISÉ SELON LA MÉTHODE DE LA PHARMACOPÉE JAPONAISE UTILISANT UN APPAREIL À PALETTE À 50 TOURS PAR MINUTE (SOLUTION DE TEST : TAMPON MCILVAINE, PH 6,0) ÉVALUE LE TAUX DE DISSOLUTION DE L'ACIDE 2-(3-CYANO-4-ISOBUTYLOXYPHÉNYL)-4-MÉTHYL-5-THIAZOLE CARBOXYLIQUE À 70 % OU PLUS APRÈS 10 MINUTES.
MA35652A 2010-07-09 2011-07-08 Préparation d'un revêtement de particules MA34460B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010156874 2010-07-09
PCT/JP2011/065721 WO2012005365A1 (fr) 2010-07-09 2011-07-08 Préparation d'un revêtement de particules

Publications (1)

Publication Number Publication Date
MA34460B1 true MA34460B1 (fr) 2013-08-01

Family

ID=45441336

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35652A MA34460B1 (fr) 2010-07-09 2011-07-08 Préparation d'un revêtement de particules

Country Status (24)

Country Link
US (1) US20130101670A1 (fr)
EP (1) EP2591781B1 (fr)
JP (1) JP5000017B2 (fr)
KR (1) KR20130113348A (fr)
CN (1) CN102958522B (fr)
AR (1) AR082139A1 (fr)
AU (1) AU2011274851A1 (fr)
BR (1) BR112013000298A2 (fr)
CA (1) CA2804874C (fr)
CL (1) CL2013000089A1 (fr)
CO (1) CO6650363A2 (fr)
EC (1) ECSP12012360A (fr)
ES (1) ES2644064T3 (fr)
MA (1) MA34460B1 (fr)
MX (1) MX2013000282A (fr)
NZ (1) NZ605562A (fr)
PE (1) PE20131064A1 (fr)
PH (1) PH12013500032A1 (fr)
RU (1) RU2013105456A (fr)
TN (1) TN2012000623A1 (fr)
TW (1) TW201217001A (fr)
UY (1) UY33499A (fr)
WO (1) WO2012005365A1 (fr)
ZA (1) ZA201300106B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20170306A1 (es) 2010-06-16 2017-05-06 Takeda Pharmaceuticals Usa Inc Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
JP5978216B2 (ja) 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド テオフィリンとフェブキソスタットの併用療法のための方法
CN106267220B (zh) * 2015-05-14 2019-06-28 北京科信必成医药科技发展有限公司 愈创甘油醚氢溴酸右美沙芬无水吞服掩味制剂
JP7108384B2 (ja) * 2016-07-13 2022-07-28 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の口腔内崩壊錠
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3731699A (en) * 1998-05-18 1999-12-06 Takeda Chemical Industries Ltd. Orally disintegrable tablets
JP4300652B2 (ja) 1998-09-21 2009-07-22 大正製薬株式会社 経口用固形製剤
JP3389205B2 (ja) 1999-06-29 2003-03-24 武田薬品工業株式会社 口腔内速崩壊錠
AP1919A (en) * 2001-11-21 2008-11-13 Eisai R&D Man Co Ltd Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same
JP2005023058A (ja) 2003-06-10 2005-01-27 Lion Corp 咀嚼型医薬製剤用薬物粒子及びその製造方法、並びに薬物粒子を含有する咀嚼型医薬固形製剤及びその製造方法
JP5062872B2 (ja) 2003-08-13 2012-10-31 東和薬品株式会社 不快な味を低減した口腔内崩壊錠剤
CA2619745A1 (fr) * 2005-08-18 2007-02-22 Teijin Pharma Limited Comprime avec des sections contenant de multiples medicaments
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
JP5123517B2 (ja) * 2005-11-14 2013-01-23 帝人ファーマ株式会社 アンブロキソール口腔内速崩性錠剤
JP2008050324A (ja) * 2006-08-28 2008-03-06 Ohara Yakuhin Kogyo Kk 苦味遮蔽組成物。
JP5097488B2 (ja) 2006-09-13 2012-12-12 京都薬品工業株式会社 苦味マスキング
PE20170306A1 (es) * 2010-06-16 2017-05-06 Takeda Pharmaceuticals Usa Inc Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa

Also Published As

Publication number Publication date
ZA201300106B (en) 2013-09-25
US20130101670A1 (en) 2013-04-25
JPWO2012005365A1 (ja) 2013-09-05
ES2644064T3 (es) 2017-11-27
CN102958522B (zh) 2015-12-16
NZ605562A (en) 2013-11-29
WO2012005365A1 (fr) 2012-01-12
MX2013000282A (es) 2013-02-11
AR082139A1 (es) 2012-11-14
EP2591781A1 (fr) 2013-05-15
CL2013000089A1 (es) 2013-03-08
UY33499A (es) 2012-01-31
JP5000017B2 (ja) 2012-08-15
CO6650363A2 (es) 2013-04-15
ECSP12012360A (es) 2013-02-28
PH12013500032A1 (en) 2013-02-11
BR112013000298A2 (pt) 2016-05-31
TW201217001A (en) 2012-05-01
RU2013105456A (ru) 2014-08-20
PE20131064A1 (es) 2013-09-23
EP2591781A4 (fr) 2014-12-03
EP2591781B1 (fr) 2017-09-27
AU2011274851A1 (en) 2013-01-31
CA2804874C (fr) 2019-07-23
TN2012000623A1 (en) 2014-04-01
CA2804874A1 (fr) 2012-01-12
KR20130113348A (ko) 2013-10-15
CN102958522A (zh) 2013-03-06

Similar Documents

Publication Publication Date Title
MA34460B1 (fr) Préparation d'un revêtement de particules
KR101826531B1 (ko) 약물 저항성 미생물 치료를 위한 메틸설포닐메탄
EP1395271B1 (fr) Compositions a base d'herbes medicinales destinees au traitement des lesions muqueuses
MA34768B1 (fr) Comprimé orodispersible
PE20091620A1 (es) Preparacion solida de desintegracion oral
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
FR2959936A1 (fr) Composition nasales a visee systemique a base de cocoyl proline ou d 'au moins un de ses constituants
JP2014224110A (ja) ロキソプロフェン含有外用剤組成物
EP3116517B1 (fr) Comprime vaginal muco-adhesif a liberation prolongee
Fehér et al. Hepatoprotective effects of a self-micro emulsifying drug delivery system containing Silybum marianum native seed oil against experimentally induced liver injury
TW200624127A (en) New modified release pellet formulations for proton pump inhibitors
JP2015521647A5 (fr)
EP1782831B1 (fr) Preparation a usage externe
TW201343163A (zh) 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物
MA37693B1 (fr) Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et application
CN104586819A (zh) 一种治疗老年痴呆病症的药物组合物及制备方法
JP6253495B2 (ja) ロキソプロフェンを含有する外用剤組成物
Nakamura et al. ETA receptor antagonist ameliorates nephrosclerosis and left ventricular hypertrophy induced in rat by prolonged inhibition of nitric oxide synthesis
MA20150424A1 (fr) Compositions liquides orales pédiatriques contenant du nepadutant
CN1215870C (zh) 一种治疗感冒的荆芥挥发油的提取方法及制剂的制备方法
JP2017518967A (ja) 進行した非アルコール性脂肪性肝炎の治療方法
TWI656878B (zh) 靈芝萃取物於抑制或降低ｐｍ.細懸浮微粒引發的毒性之用途
CN111603463A (zh) 脱氢去乙酰氧母菊素或去乙酰母菊酮素在制备降糖降脂药物中的应用
ZA201102353B (en) A parasiticidal composition
FR2581312A1 (fr) Formulation pharmaceutique et procede pour proteger des malades contre les effets secondaires du cis-platine